Literature DB >> 11053202

Discontinuation rates for use of statins are high.

L A Simons, J Simons, P McManus, J Dudley.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11053202      PMCID： PMC1118863     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Use of statins in general practices, 1996-8: cross sectional study.

Authors:  C Packham; J Pearson; J Robinson; D Gray
Journal:  BMJ       Date:  2000-06-10

2.  Cholesterol reduction yields clinical benefit: impact of statin trials.

Authors:  A L Gould; J E Rossouw; N C Santanello; J F Heyse; C D Furberg
Journal:  Circulation       Date:  1998-03-17       Impact factor: 29.690

3.  Apparent discontinuation rates in patients prescribed lipid-lowering drugs.

Authors:  L A Simons; G Levis; J Simons
Journal:  Med J Aust       Date:  1996-02-19       Impact factor: 7.738
  3 in total
  10 in total

1.  High persistence of statin use in a Danish population: compliance study 1993-1998.

Authors:  John Larsen; Morten Andersen; Jakob Kragstrup; Lars F Gram
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

2.  Statin-associated weakness in myasthenia gravis: a case report.

Authors:  Michael J Keogh; John M Findlay; Simon Leach; John Bowen
Journal:  J Med Case Rep       Date:  2010-02-20

3.  HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival.

Authors:  Nizar Younas; Christine M Wu; Ron Shapiro; Jerry McCauley; James Johnston; Henkie Tan; Amit Basu; Heidi Schaefer; Cynthia Smetanka; Wolfgang C Winkelmayer; Mark Unruh
Journal:  BMC Nephrol       Date:  2010-04-01       Impact factor: 2.388

4.  Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Toine C G Egberts; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Authors:  Linda J Cobiac; Anne Magnus; Jan J Barendregt; Rob Carter; Theo Vos
Journal:  BMC Public Health       Date:  2012-06-01       Impact factor: 3.295

6.  Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

Authors:  Matthew T Mefford; Gabriel S Tajeu; Rikki M Tanner; Lisandro D Colantonio; Keri L Monda; Ricardo Dent; Michael E Farkouh; Robert S Rosenson; Monika M Safford; Paul Muntner
Journal:  Am J Cardiol       Date:  2018-06-02       Impact factor: 3.133

7.  A new paradigm for primary prevention strategy in people with elevated risk of stroke.

Authors:  Valery L Feigin; Bo Norrving
Journal:  Int J Stroke       Date:  2014-07       Impact factor: 5.266

8.  Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients.

Authors:  Abhinav Grover; Harmeet Singh Rehan; Lalit Kumar Gupta; Madhur Yadav
Journal:  Indian Heart J       Date:  2016-08-01

9.  Effects of different statins application methods on plaques in patients with coronary atherosclerosis.

Authors:  Xia Wu; Xiao-Bo Liu; Ting Liu; Wen Tian; Yu-Jiao Sun
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

10.  Which interventions offer best value for money in primary prevention of cardiovascular disease?

Authors:  Linda J Cobiac; Anne Magnus; Stephen Lim; Jan J Barendregt; Rob Carter; Theo Vos
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.